|Description||BX-517, also known as PDK1 inhibitor2, is a cell-permeable indolinone compound that acts as a potent, ATP site-targeting PDK1 inhibitor (IC50 = 6 nM). BX-517 also blocks activation of Akt in tumor cells with 10-fold more potent (IC50 = 0.1–1.0 μM) than its analogs tested at the highest dose tested (10 μM).|
|Synonyms||(Z)-N-(3-(1-(1H-pyrrol-2-yl)ethylidene)-2-hydroxy-3H-indol-5-yl)carbamimidic acid; BX-517; BX 517; BX517; PDK1 inhibitor2.|
|Storage||Store in a cool and dry place (or refer to the Certificate of Analysis).|
|Boiling Point||572.4±50.0 °C at 760 Torr|
BX-517, also known as PDK1 inhibitor2, is a cell-permeable indolinone compound that acts as a potent, ATP site-targeting PDK1 inhibitor (IC50 = 6 nM). BX-517 al...
NVP-BAG956 is a potent, ATP-competitive and selective dual PI3K and PDK1 inhibitor in vitro and in vivo. It inhibits cellular AKT phosphorylation at Thr308 and ...
TEPP-46, an effective sensitizer of recombinant pyruvate kinase M2, has been found to decrease the formation of tumor in a mouse xenograft model. IC50: 92 nM (A...
BX-912 is a selective inhibitor of 3-Phosphoinositide-dependent Kinase-1 (PDK1) with IC50 of 12 nM; >10 fold selectivity over PKA, PKC, C-Kit, EGFR etc.
GSK2334470 is a potent 3-phosphoinositide-dependent protein kinase (PDK1) inhibitor (IC50 ~ 10 nM), which does not suppress the activity of 93 other protein kin...
OSU 03012, a Phenanthren derivative, has been found to be a PDPK1 inhibitor that could probably be an effctive antitumor agent. It is still under Phase I trail ...
PDK1 inhibitor is a potent and selective inhibitor of PDK1 with potential as anticancer agent.